Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AEHAW
Aesther Healthcare Acquisition
$0.01
$0.01
$0.06
$0.33
N/AN/A34,287 shsN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
$0.46
-16.3%
$0.03
$0.00
$0.62
N/AN/A493,603 shs5.19 million shs
LBPSW
4D pharma
$0.00
$0.04
$1.29
N/AN/A20,931 shsN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.82
+0.3%
$1.83
$1.15
$3.00
N/A-0.3214,562 shs9,820 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AEHAW
Aesther Healthcare Acquisition
0.00%0.00%+276.92%-49.74%-68.39%
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
-16.36%+4,500.00%+6,033.33%+6,566.67%+4,239.62%
LBPSW
4D pharma
0.00%0.00%0.00%0.00%0.00%
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
+0.28%+2.25%+0.08%+21.00%-35.87%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
4.1125 of 5 stars
3.03.00.04.63.30.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AEHAW
Aesther Healthcare Acquisition
0.00
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
0.00
N/AN/AN/A
LBPSW
4D pharma
0.00
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
2.00
Hold$5.00175.48% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/AN/A
LBPSW
4D pharma
$522KN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/A$0.21 per share8.66($3.67) per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AEHAW
Aesther Healthcare Acquisition
N/AN/A0.00N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/A0.00N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/A0.00N/AN/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
$1.44M$0.822.21N/AN/AN/A-20.68%15.73%8/19/2025 (Estimated)

Latest NERV, ATNFW, LBPSW, and AEHAW Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/19/2025Q2 2025
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
-$0.95-$0.43+$0.52-$0.43N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/AN/AN/A
LBPSW
4D pharma
N/AN/AN/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AEHAW
Aesther Healthcare Acquisition
N/AN/AN/A
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
N/AN/AN/A
LBPSW
4D pharma
N/AN/AN/A
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
N/A
9.21
9.21
CompanyEmployeesShares OutstandingFree FloatOptionable
AEHAW
Aesther Healthcare Acquisition
2N/AN/ANot Optionable
180 Life Sciences Corp. stock logo
ATNFW
180 Life Sciences
7N/AN/ANot Optionable
LBPSW
4D pharma
N/AN/AN/ANot Optionable
Minerva Neurosciences, Inc stock logo
NERV
Minerva Neurosciences
9N/AN/ANot Optionable

Recent News About These Companies

Stocks to Watch: Gambling.com, GrabAGun, Minerva Neurosciences
Free concert on Minerva’s Municipal Park Stage

Media Sentiment Over Time

Top Headlines

View All Headlines

Aesther Healthcare Acquisition NASDAQ:AEHAW

$0.0098 0.00 (0.00%)
As of 08/8/2025

Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.

180 Life Sciences stock logo

180 Life Sciences NASDAQ:ATNFW

$0.46 -0.09 (-16.35%)
As of 08/14/2025 03:59 PM Eastern

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed phase 2a and phase 2b proof-of-concept clinical trials for early-stage Dupuytren's Contracture; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, that focuses on alpha 7 nicotinic acetylcholine receptor. 180 Life Sciences Corp. is headquartered in Palo Alto, California.

4D pharma NASDAQ:LBPSW

4D pharma plc, together with its subsidiaries, engages in the research, development, and production of live biotherapeutic products. The company develops therapeutic candidates, such as MRx0518; MRx-4DP000 for the treatment of asthma and COVID-19; MRx0029 the treatment of central nervous system disorders; Blautix for irritable bowel syndrome; and Thetanix for pediatric crohn's disease. It also develops products candidates, including MRx1299 for solid tumors, MRx0005 for neurodegeneration, MRx0006 for rheumatoid arthritis, and MRx0002 for multiple sclerosis. The company develops MicroRx platform to discover new LBP candidates for major diseases. 4D pharma plc has a collaboration agreement with Merck & Co., Inc. to conduct a clinical trial evaluating the combination of Keytruda and MRx0518 in patients with solid tumors. The company was formerly known as Schosween 18 Limited. 4D pharma plc was incorporated in 2014 and is headquartered in Leeds, the United Kingdom.

Minerva Neurosciences stock logo

Minerva Neurosciences NASDAQ:NERV

$1.82 +0.01 (+0.28%)
Closing price 08/14/2025 03:48 PM Eastern
Extended Trading
$1.89 +0.08 (+4.13%)
As of 08/14/2025 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.